Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis

Published:2017-07-17 Issue:10 Volume:31 Page:1627-1632
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Amin M.¹,Darji K.²,No D.J.³,Wu J.J.⁴

Affiliation:

1. School of Medicine; University of California, Riverside; Riverside CA USA

2. School of Medicine; Saint Louis University; St. Louis MO USA

3. School of Medicine; Loma Linda University; Loma Linda CA USA

4. Department of Dermatology; Kaiser Permanente Los Angeles Medical Center; Los Angeles CA USA

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.14451/fullpdf

Reference25 articles.

1. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use;Takeshita;J Invest Dermatol,2015

2. Cytokines in psoriasis;Baliwag;Cytokine,2015

3. Pathogenesis and therapy of psoriasis;Lowes;Nature,2007

4. Specific targeting of interleukin-23p19 as effective treatment for psoriasis;Levin;J Am Acad Dermatol,2014

5. New and emergic biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors;Gaspari;Dermatol Ther,2015

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation;Journal of the European Academy of Dermatology and Venereology;2023-06-02

2. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics;Italian Journal of Dermatology and Venereology;2023-01

3. Interleukin-23 Inhibitors;TURKDERM;2022-05-05

4. Relationship between Immune Cells, Depression, Stress, and Psoriasis: Could the Use of Natural Products Be Helpful?;Molecules;2022-03-17

5. Treating patients with moderate-to-severe psoriasis vulgaris;JAAPA;2022-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3